Orphan Drug Access: One-Third Of US Coverage Decisions Involve Restrictions, Study Finds
Executive Summary
Tufts researchers report restrictions are more common for orphan drugs indicated for diseases with higher prevalence and that are more expensive.
You may also be interested in...
Commercial Coverage For Specialty Drugs Lacks Consistency, Study Finds
Coverage decisions are also often more restrictive than drug labeling, according to researchers from Tufts.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.